Clinical Trials Logo

Hepatic Veno-Occlusive Disease clinical trials

View clinical trials related to Hepatic Veno-Occlusive Disease.

Filter by:

NCT ID: NCT00358501 Completed - Clinical trials for Severe Hepatic Veno Occlusive Disease

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

Start date: July 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endothelial markers of VOD through the analysis of blood samples.

NCT ID: NCT00272948 Completed - Clinical trials for Hepatic Veno-Occlusive Disease

Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide

VOD-DF
Start date: December 2005
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this trial is to evaluate whether the prophylactic use of Defibrotide (DF) in pediatric patients (age less than 18 years) undergoing stem cell transplantation and who are at high risk of developing hepatic Veno-occlusive Disease (VOD) will have an impact on the incidence and severity of the disease. Patients will be randomly assigned to one of two treatment arms: Those allocated to the Prophylactic Arm will receive the study drug (Defibrotide) from the day of conditioning onwards. Patients allocated to the Control Arm will receive the study drug (Defibrotide) from the day that VOD is diagnosed.

NCT ID: NCT00263978 No longer available - Liver Diseases Clinical Trials

Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver

Start date: November 2005
Phase: N/A
Study type: Expanded Access

Severe veno-occlusive disease (VOD) of the liver is a life threatening complication of blood and marrow transplantation. Treatment with currently available (Food and Drug Administration [FDA] approved) agents fails in most cases. Recently conducted clinical studies indicate that patients benefit from defibrotide, a non-FDA approved agent. This protocol has been developed not with a research intent, but rather to ensure that defibrotide is used by the blood and marrow transplant programs at Children's Healthcare of Atlanta and at Emory University in a safe, effective and ethical manner.

NCT ID: NCT00143546 No longer available - Clinical trials for Hepatic Veno-occlusive Disease

Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver

Start date: November 2003
Phase: N/A
Study type: Expanded Access

Veno-occlusive disease (VOD) of the liver is a significant complication for some patients undergoing hematopoietic stem cell transplantation. This disease is thought to be a toxicity secondary to chemotherapy or radiation-induced damage to the epithelial cells of the blood vessels in the liver. VOD is categorized as mild, moderate or severe. Historically, there has been no method to treat the disease. Recently, however, there have been investigations into the use of a new agent called defibrotide. The primary purpose of this protocol is to provide defibrotide to patients with severe VOD. Because this drug has not been approved by the FDA, use of this medication under the auspices of this IND treatment plan is for compassionate use only.